Identify Novel Antibody Target Pairs To Advance Targeted Immunotherapies

Our SPARTA technology utilizes in vivo screening to identify antibodies and drug targets for use in antibody-drug conjugates (ADCs).

SPARTA - Robust antibody and drug target selection that goes beyond in vitro screening

Traditional in vitro antibody selection methods may produce promising candidates, but many fail when introduced into a complex, in vivo tumor microenvironment.

Common causes for failure of in vitro-selected antibodies

Lack of selectivity of antibody to the tumor tissue compared to normal tissue in vivo

Inability of antibody to access the tumor microenvironment in vivo

Failure of antibody to internalize into tumor tissue

Masking of binding epitopes on tumor cells due to the complexity of the tumor microenvironment

The SPARTA approach picks up where in vitro screening methods end. With SPARTA, antibody selection occurs in vivo and is based on observed pharmacokinetics.

With SPARTA’s in vivo selection, antibodies can be confirmed to:

Exit the bloodstream and localize to the tumor

Bind native tumor proteins and avoid healthy tissues

Enter into the tumor cell

Exhibit stability, sufficient for use in therapeutic applications

Confirmation of antibody activity and specificity against tumor cells in vivo results in the selection of improved antibody candidates for ADC development. The identified antibodies increase efficacy and decrease the potential for off-target toxicity when used as a component of an ADC.

In addition, since SPARTA identifies antibody-target pairs that display robust internalization, the selected antibodies have an increased likelihood of providing efficient and specific toxin delivery to cancer cells.

Proprietary Technology for Producing Antibodies to Intracellular Targets

Proprietary Technology for Producing Antibodies to Intracellular Targets

Certain intracellular proteins critical for cellular function translocate to the surface of cancer cells, particularly when the cells are under stress. This relocation to the cell surface makes these targets particularly good candidates for ADC development. The production of monoclonal antibodies against intracellular targets may, however, reduce viability of the manufacturing cells, thus leading to significant challenges in the production of these antibodies.

MBrace has developed a novel, proprietary approach to the manufacture of antibodies against intracellular targets that allows sufficient expression of the antibodies while maintaining the function of the native target in the manufacturing cells or system. This approach allows these intracellular targets to be viable antibody drug targets – many for the very first time. MBrace has three international patent families pending covering production of antibodies to intracellular drug targets, including antibodies against the target of our second ADC program.

Discover new targets for drug development

Reveal therapeutic targets present across many cancer types

Decrease drug side effects through high antibody specificity

Discovering novel antibody-drug target pairs for ADC development

Take a closer look at how SPARTA combines in vitro and in vivo selection methods to accelerate ADC development.

Antibody-based cancer drugs in development

Learn about antibody-drug conjugates (ADCs) in our development pipeline and explore clinical trial opportunities.

Additional resources

Understanding antibody-drug conjugates

Learn about our clinical program

Additional resources

Understanding antibody-drug conjugates

Learn about our clinical program

For more information about MBrace’s products or programs please contact us at: